case_images: PMC10624121_01
case_images: (A-F) Patients (A-D) hypersensitivity reactions.
case_images: fendo-14-1226231-g001.jpg
case_images: PMC10624121_04_fendo-14-1226231-g001.jpg
case_images: f1
case_images: He tolerated glulisine for 6 years, but upon transitioning to insulin aspart, the patient developed erythematous, firm, tender nodules presenting several hours after injection and lasting several days ( Figure 1F ).
case_images: PMC10624121_02
case_images: (A-F) Patients (A-D) hypersensitivity reactions.
case_images: fendo-14-1226231-g001.jpg
case_images: PMC10624121_04_fendo-14-1226231-g001.jpg
case_images: f1
case_images: He tolerated glulisine for 6 years, but upon transitioning to insulin aspart, the patient developed erythematous, firm, tender nodules presenting several hours after injection and lasting several days ( Figure 1F ).
case_images: PMC10624121_03
case_images: (A-F) Patients (A-D) hypersensitivity reactions.
case_images: fendo-14-1226231-g001.jpg
case_images: PMC10624121_04_fendo-14-1226231-g001.jpg
case_images: f1
case_images: He tolerated glulisine for 6 years, but upon transitioning to insulin aspart, the patient developed erythematous, firm, tender nodules presenting several hours after injection and lasting several days ( Figure 1F ).
case_images: PMC10624121_04
case_images: (A-F) Patients (A-D) hypersensitivity reactions.
case_images: fendo-14-1226231-g001.jpg
case_images: PMC10624121_04_fendo-14-1226231-g001.jpg
case_images: f1
case_images: He tolerated glulisine for 6 years, but upon transitioning to insulin aspart, the patient developed erythematous, firm, tender nodules presenting several hours after injection and lasting several days ( Figure 1F ).